SCHEMBL29334274

SCHEMBL29334274

CC(C)(C)OC(=O)N1C(=O)COC[C@H]1CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.41
NR1H2 P55055 1/20 0.38
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
GAA P10253 1/20 0.34
RECQL P46063 1/20 0.33
KLK7 P49862 1/20 0.32
TPSAB1 Q15661 1/20 0.31
TPSD1 Q9BZJ3 1/20 0.31
TPSG1 Q9NRR2 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28717400 0.82 GLA (0.38) GLAUSP2SMN1; SMN2CHRM2CHRM1
SCHEMBL24700403 0.81 USP2 (0.39) GLAUSP2SMN1; SMN2CHRM2CHRM1
SCHEMBL12901412 0.81 USP2 (0.39) GLAUSP2SMN1; SMN2CHRM2CHRM1
SCHEMBL23522781 0.81 USP2 (0.39) GLAUSP2SMN1; SMN2CHRM2CHRM1
SCHEMBL23455637 0.79 NR1H2 (0.40) GLANR1H2USP2SMN1; SMN2CHRM2
SCHEMBL8055691 0.78 GLA (0.37) GLACHRM2CHRM1CHRM3KLK7
SCHEMBL8055452 0.78 GLA (0.37) GLACHRM2CHRM1CHRM3KLK7
SCHEMBL31048365 0.78 NR1H2 (0.37) GLANR1H2USP2SMN1; SMN2GAA
SCHEMBL24250115 0.78 NR1H2 (0.41) GLANR1H2CHRM2CHRM1CHRM3
SCHEMBL13482907 0.78 NR1H2 (0.41) GLANR1H2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226114-A1 INHIBITORS AND USES THEREOF KEAP1, NQO1, NFE2L2 GLA 2825/4885NR1H2 55/4885USP2 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.